Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.65 |
| ▸ | MME | P08473 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.62 |
| ▸ | RXRA | P19793 | 3/20 | 0.58 |
| ▸ | RXRB | P28702 | 3/20 | 0.58 |
| ▸ | RXRG | P48443 | 3/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691972 | 0.85 | RXRA (0.74) | SLC13A5MMEMAOBRXRARXRB | |
| SCHEMBL12646504 | 0.83 | MAOB (0.57) | SLC13A5FFAR1MMEMAOBFFAR4 | |
| SCHEMBL365336 | 0.83 | FFAR1 (0.70) | FFAR1FFAR4S1PR5THRATHRB | |
| Hydrochloric Acid SCHEMBL30765594 | 0.81 | FFAR1 (0.68) | FFAR1FFAR4S1PR5THRATHRB | |
| SCHEMBL1744998 | 0.80 | FFAR1 (0.78) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL1550659 | 0.79 | FFAR1 (1.00) | FFAR1FFAR4 | |
| SCHEMBL117230 | 0.79 | FFAR1 (0.73) | FFAR1FFAR4 | |
| SCHEMBL8618654 | 0.79 | FFAR1 (1.00) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL1211561 | 0.79 | FFAR1 (1.00) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL2873036 | 0.78 | MME (1.00) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| WO-2010012650-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2010-02-04 | — | — | WO | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | SLC13A5 1348/4885FFAR1 6/4885MME 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.